BioSpace News Archive

Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces the participation of members of the company’s senior management team in two investor conferences being held virtually during June 2021.

Transgene and BioInvent International AB announce that their Investigational New Drug application for BT-001 has been granted by the U.S. Food and Drug Administration.

ONK Therapeutics Ltd, an innovative natural killer cell therapy company, announced that it has entered into an exclusive global patent license agreement with Australia’s Walter and Eliza Hall Institute of Medical Research providing rights to CISH KO in the field of NK cells for the treatment of cancer.

Repeated immunization with AFFITOPE® peptide active immunotherapy candidates AT04A and AT06A is safe, well-tolerated and induces a strong and long-lasting PCSK9-specific immune response

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) is pleased to highlight an independent research study from the University of Szeged in Hungary describing the use of N,N-dimethyltryptamine (“DMT”) in improving outcomes in a rat stroke model.

Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced the nomination of its first Synthetic viral RNA (vRNA) immunotherapy clinical candidates, ONCR-021 and ONCR-788.

Rezolute, Inc., a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases related to chronic glucose imbalance, announced that Nevan Charles Elam, CEO and Founder, will present at two upcoming virtual investment conferences.

Bill Desmarais, Ph.D., MBA, named Chief Business Officer, bringing more than 20 years of business development and partnering experience Oncology drug development veteran Gabriela Gruia, M.D., appointed to Board of Directors Timothy Barberich named Chair of Board of Directors

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced that management will participate in the following virtual investor conferences in June: Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021; fireside chat at 11:00 a.m. ET

Tectonic Therapeutic , a pre-clinical stage biotechnology company transforming the discovery of novel G-protein-coupled receptors (GPCR)-targeted therapies, today announced that Peter McNamara, PhD has been appointed Senior Vice President, Head of Research.